From Chengdu To The World: Anticancer Takes Novel Approach To Cancer Drug Development
Inspired by the discovery of the phytochemical corynoline being a potential MYC synthetic lethality agent, Anticancer Bioscience has designed and identified preclinical candidates that could lead to first-in-class innovative drugs.
You may also be interested in...
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
A Chinese court decision sheds light on how Chinese major Hengrui Medicine is seeking to reduce or avoid potential losses worth up to $27m following regulatory setbacks with the tubulin inhibitor plinabulin, in-licensed from BeyondSpring in 2021.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.